To conclude, the development of an ovarian cancer vaccine based on exosomes from the ascites fluid of ovarian cancer patients and the TLR3 agonist poly[I]:poly[C12U] (Ampligen®) is currently being prepared for phase I clinical testing [96]. This evidence concerns the gene TLR3 and ovarian cancer.